Qin Wang,
Scientist, Drug Safety Research & Evaluation
Dr. Wang received a Ph.D in Molecular Toxicology and Master degree in Biostatistics from the University of Cincinnati. After finished one year’s postdoctoral training in computational toxicity, Dr. Wang moved to Drug Safety Research & Evaluation of Takeda Pharmaceuticals in early 2017, where she designs, develops and implements custom microtissue models to improve the safety profile of drug discovery portfolio, with a focus on bone marrow and CNS toxicities. Dr. Wang uses in vitro de-risking strategies to aid in the selection and optimization of large and small molecular therapeutics. Research interests include new modalities-caused CNS toxicities, and application of iPSC-derived 3D models to de-risk toxicities in early drug discovery.
|
|
|
